ArticleMedical physics2025
RapidBrachyIVBT: A dosimetry software for patient-specific intravascular brachytherapy dose calculations on optical coherence tomography images.
Article in Medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Impact of IVUS Guidance on Clinical and Procedural Outcomes in Intracoronary Brachytherapy.JACC. Advances · 2026Article
- Intracoronary Imaging in Brachytherapy: Opportunity Knocks.JACC. Advances · 2026Article
- RapidBrachyIVBT: A dosimetry software for patient-specific intravascular brachytherapy dose calculations on optical coherence tomography images.Medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCoronary artery disease is the most common form of cardiovascular disease. It is caused by excess plaque along the arterial wall, blocking blood flow to the heart (stenosis). A percutaneous coronary intervention widens the arterial wall with the inflation of a balloon inside the lesion area and leaves behind a metal stent to prevent re-narrowing of the artery (restenosis). However, in-stent restenosis may occur due to damage to the arterial wall tissue, triggering neointimal hyperplasia, producing fibrotic and calcified plaques and narrowing the artery again. Drug-eluting stents, which slowly release medication to inhibit neointimal hyperplasia, are used to prevent in-stent restenosis but fail up to 20% of cases. Coronary intravascular brachytherapy (IVBT), which uses PURPOSE: This study aimed to develop a Monte Carlo-based dose calculation software, accounting for patient-specific geometry from Optical Coherence Tomography (OCT) images.
methodsRapidBrachyIVBT, a Monte Carlo dose calculation software based on the Geant4 toolkit v. 10.02.p02, was developed and integrated into RapidBrachyMCTPS, a treatment planning system for brachytherapy applications. The only commercially available IVBT delivery system, the Novoste Beta-Cath 3.5F, with a
resultsThe dose rate values in water obtained using RapidBrachyIVBT aligned with TG-149 consensus values, showing agreement within a range of 0.03% to 1.7%. Considering the heterogeneities present in the patient's OCT images, the absorbed dose in the entire artery segment was up to 77.5% lower, while within the target volume, it was up to 56.6% lower, compared to the dose calculated in a homogeneous water phantom.
conclusionRapidBrachyIVBT, a Monte Carlo dose calculation software for IVBT, was developed and successfully integrated into RapidBrachyMCTPS, a treatment planning system for brachytherapy applications, where accurate attenuation of the absorbed dose by heterogeneities is considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.